Key result
Sevelamer did not significantly lower mean end-treatment serum phosphate levels compared to placebo in patients with aortic stenosis (3.31 mg/dL with high-dose vs 3.38 mg/dL with placebo).
Why the study?
Serum phosphate is associated with aortic stenosis, but it is uncertain whether phosphate-binding drugs lower serum phosphate levels in patients without diagnosed renal failure.
Does sevelamer reduce serum phosphate levels in patients with aortic stenosis without diagnosed renal failure?
RCT (n=72)
Double-blind
Crossover
Does sevelamer reduce serum phosphate levels in patients with aortic stenosis without diagnosed renal failure?
In patients with aortic stenosis, sevelamer did not significantly lower overall serum phosphate levels, though it may reduce levels in patients with the highest baseline phosphate.
Purpose Aortic stenosis is a common cause of valvular heart disease with no means of prevention. The recognized association between aortic stenosis and serum phosphate raises the possibility of preventing progression of the disorder by using phosphate-binding drugs, but there is uncertainty whether such treatment lowers serum phosphate levels in patients without diagnosed renal failure. This pilot study was conducted to answer this question in patients with aortic stenosis. Methods A randomized, double-blind, crossover trial of the phosphate-binding drug sevelamer was conducted in 72 patients. Patients were prescribed sevelamer 0.8 g (low-dose), sevelamer 2.4 g (high-dose), and matching placebo, 3 times daily with food; each regimen lasted 6 weeks and was allocated at random. Serum phosphate levels were measured at the end of each treatment period, and within-person levels were compared. Findings Sixty-one patients completed the 3 treatment periods. There was no significant difference in the mean end-treatment phosphate levels across all patients (3.38, 3.36, and 3.31 mg/dL with placebo, low-dose sevelamer, and high-dose sevelamer, respectively). Post hoc analysis showed a reduction in phosphate levels with increasing sevelamer dose in the highest baseline phosphate quartile group; a 0.3 mg/dL reduction (mean, 4.09 mg/dL with placebo, 3.95 mg/dL with low-dose sevelamer, and 3.79 mg/dL with high-dose sevelamer; P trend = 0.027). Implications Sevelamer had no overall statistically significant effect in lowering serum phosphate levels, but a reduction was observed in patients with phosphate levels in the highest quartile group of the population distribution. This hypothesis-generating result requires confirmation in an independent study. If confirmed, a trial of sevelamer in preventing the progression of aortic stenosis may be justified in patients with high phosphate levels. ISRCTN Registry identifier: ISRCTN17365679.
No takes yet. Share an insight, caveat, or question.
Wald et al. (2019) conducted an RCT in Aortic stenosis (n=72). Sevelamer vs. Placebo was evaluated on Mean end-treatment serum phosphate levels. Sevelamer did not significantly lower mean end-treatment serum phosphate levels compared to placebo in patients with aortic stenosis (3.31 mg/dL with high-dose vs 3.38 mg/dL with placebo).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: